Characterization of the efficacies of osimertinib and nazartinib against cells expressing clinically relevant epidermal growth factor receptor mutations

Keita Masuzawa(Keio University), Tomoko Betsuyaku(Keio University)
Oncotarget
November 6, 2017
Cited by 55


Related Papers